Alembic Pharmaceuticals has received the Food and Drug Administration's approval for bromfenac ophthalmic solution 0.09%.

The product is the generic of Bausch & Lomb’s Bromday ophthalmic solution, 0.09%.

It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Bromfenac ophthalmic solution 0.09% has a market value of $6 million for the 12 months ending December 2018, according to IQVIA.